Untitled 3

Source R&D is the authoritative source of technology and services information supporting pharmaceutical and biotechnology companies in their drug discovery and development research projects.

Source R&D features extensive listings of service providers classified under company or organisation type, including contract chemical manufacturers; contract biologics manufacturers; biological research companies and organisations; and companies and organisations providing advisory, consultancy, legal, regulatory and other services.

The extensive coverage of Source R&D and the support of life sciences organisations One Nucleus and Bionow make it an invaluable reference tool that streamlines the vendor selection process to bring pharmaceutical/biotechnology companies and suppliers together.

Horizon Discovery extends CRISPR Screening Service to primary human T cells

Horizon Discovery logo 26.1.19Horizon Discovery Group plc has extended its CRISPR Screening Service to include ex-vivo T lymphocytes. CRISPR screens in primary T lymphocytes have proved challenging, owing to complex issues around the introduction of the screening components and Cas9 in particular. Horizon has adapted its established CRISPRko (knockout) platform to address these issues and to deliver a robust screening platform in human T lymphocytes, which will enable complex biological processes, novel targets and more effective drug therapies to be investigated in a therapeutically relevant cell type. The new screening service complements the company’s established CRISPR screening formats – CRISPRko, CRISPRi (interference) and CRISPRa (activation) – in cancer cell lines.

For further information about Horizon Discovery Group plc visit www.horizondiscovery.com

Last modified onFriday, 01 February 2019 11:34